Cutaneous Adverse Drug Reactions

我们继续评价发生皮肤药物不良反应（例如药物超敏反应综合征）的患者，包括存在发生与分子靶向治疗相关的皮肤毒性风险的患者。这些评价包括治疗开始前的基线评价和随访访视，以监测和治疗这些皮肤毒性。我们以前曾与肿瘤学同事合作，并将继续与肿瘤学同事合作a）优化设计治疗方案，以评估和治疗皮肤毒性，以及B）通过多篇同行评议的出版物和壁内和壁外讲座，向研究界通报潜在的新描述的皮肤毒性和管理这些不良反应的方法，以优化肿瘤患者的持续治疗。

We have continued to evaluate patients with cutaneous adverse drug reactions (e.g. drug hypersensitivity syndromes) including patients at risk for the development of cutaneous toxicities associated with molecularly targeted therapies. These evaluations include baseline evaluations prior to initiation of treatment and follow-up visits to monitor and treat these skin toxicities. We previously have worked and continue to work with oncology colleagues a) to optimally design treatment protocols to evaluate for and treat cutaneous toxicities, and b) to inform the research community of potentially newly described skin toxicities and methods for management of these adverse effects to optimize continued antineoplastic treatment of oncology patients through multiple peer-reviewed publications and lectures intramurally and extramurally.